Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Helper-free foamy virus vectors

G D Trobridge1, D W Russell

  • 1Markey Molecular Medicine Center and Department of Medicine, University of Washington, Seattle 98195-7720, USA.

Human Gene Therapy
|December 16, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peripheral inflammatory cytokines and motor symptoms in persons with Parkinson's disease.

Brain, behavior, & immunity - health·2022
Same author

The validity of surface EMG of extra-diaphragmatic muscles in assessing respiratory responses during mechanical ventilation: A systematic review.

Pulmonology·2020
Same author

Benzyloxycarbonyl-proline-prolinal (ZPP): Dual complementary roles for neutrophil inhibition.

Biochemical and biophysical research communications·2019
Same author

Narrative approach in understanding the drivers for resilience of military combat medics.

Journal of the Royal Army Medical Corps·2017
Same author

Evidence for the in vivo safety of insulated foamy viral vectors.

Gene therapy·2016
Same author

Mitochondria-focused gene expression profile reveals common pathways and CPT1B dysregulation in both rodent stress model and human subjects with PTSD.

Translational psychiatry·2015
Same journal

Genome Editing for Familial Hemophagocytic Lymphohistiocytosis: Design Principles, Challenges, and Translational Perspectives.

Human gene therapy·2026
Same journal

Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration.

Human gene therapy·2026
Same journal

Hyperthermia-Enhanced Adeno-Associated Virus Gene Therapy: Mechanisms, Delivery Technologies, and Translational Potential.

Human gene therapy·2026
Same journal

Adeno-Associated Virus Gene Therapy Translation: Lessons from Early Regulatory Meetings.

Human gene therapy·2026
Same journal

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026
Same journal

<i>In Vivo</i> Genome Editing Approach to Disrupt Hydroxyacid Oxidase 1 for the Treatment of Primary Hyperoxaluria Type 1.

Human gene therapy·2026
See all related articles

Researchers developed a novel method for producing safe human foamy virus (HFV) gene therapy vectors. These HFV vectors are free of helper virus, ensuring enhanced safety for gene therapy applications.

Area of Science:

  • Gene Therapy
  • Retroviral Vectors
  • Molecular Biology

Background:

  • Human foamy virus (HFV) based retroviral vectors show potential for gene therapy.
  • Production of safe and efficient HFV vectors is crucial for clinical applications.

Purpose of the Study:

  • To develop a method for producing HFV vector stocks free of detectable helper virus.
  • To engineer HFV vectors that are replication-competent retrovirus (RCR)-free.

Main Methods:

  • Utilized helper and vector plasmid constructs lacking HFV bel genes to prevent wild-type virus generation.
  • Employed a fusion promoter combining cytomegalovirus (CMV) and HFV long terminal repeat (LTR) for gene expression.
  • Produced vector stocks via transient transfection and assessed RCR using LTR trans-activation and a novel marker rescue assay.

Related Experiment Videos

Main Results:

  • Achieved HFV vector titers greater than 10(5) transducing units/ml.
  • Confirmed integration of HFV vector proviruses without deletions or rearrangements in transduced cells.
  • Demonstrated that generated vector stocks were free of RCR.

Conclusions:

  • The described method enables the production of helper-virus-free HFV vector stocks.
  • The engineered HFV vectors are safe and suitable for gene therapy applications.
  • The developed assay effectively detects Bel-independent RCR.